ArticleDiscover oncology2025
Clinical significance of ANXA9 expression in colorectal cancer and its impact on immune evasion and drug resistance.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting theBiomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a major global health challenge, creating an urgent need to find new biomarkers that improve early detection and treatment success. While studies suggest that ANXA9 contributes to cancer development, its expression in CRC and its links to prognosis, immune evasion, and resistance are poorly understood.
methodsThis study conducted bioinformatics analysis of gene expression data from the TCGA and GEO to evaluate the prognostic and diagnostic potential of ANXA9. Kaplan-Meier survival analysis and ROC curves were employed to assess these capabilities. Furthermore, ANXA9 gene mutations were examined using cBioPortal, and promoter methylation levels were analyzed via UALCAN. Enrichment, immune infiltration, and treatment response analyses were also performed on ANXA9.
resultsOur research demonstrates that ANXA9 expression is significantly elevated in CRC tissues compared to normal tissues. This elevation is associated with pathological staging and TNM classification. Kaplan-Meier analysis reveals that increased ANXA9 levels are correlated with reduced overall survival and disease-specific survival. Furthermore, several mutations in ANXA9 have been identified, accompanied by a significant reduction in promoter methylation levels. Genes related to ANXA9 are significantly enriched in pathways involved in immune responses, such as cytokine secretion and T cell activation. We also observed a correlation between ANXA9 expression and the infiltration of immune cells, particularly M1 macrophages. ANXA9 expression is linked to increased levels of the immune checkpoint gene IGSF8 and resistance to chemotherapeutic agents.
conclusionThis study reveals the critical role of ANXA9 in colorectal cancer. Its increased expression is closely associated with poor prognosis, immune evasion, and chemotherapy resistance. This provides valuable evidence for future clinical research and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.